Therefore, larger prospective randomized controlled studies are needed to evaluate the optimal timing and dosage of HCG to be given with GnRH-a trigger to maintain assisted reproductive technology outcome without increasing the risk of clinically significant OHSS. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.